Development of Hif1a Pharmacogenomic Mutation Models to Study Individual Variations in Drug Action for Tumor Hypoxia | Zendy

Vaisali Balasubramaniam | Zendy; P. K. Krishnan Namboori | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Development of Hif1a Pharmacogenomic Mutation Models to Study Individual Variations in Drug Action for Tumor Hypoxia

Author(s) -

Vaisali Balasubramaniam,

P. K. Krishnan Namboori

Publication year - 2021

Publication title -

journal of pharmacy and bioallied sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.268

H-Index - 36

eISSN - 0976-4879

pISSN - 0975-7406

DOI - 10.4103/jpbs.jpbs_766_21

Subject(s) - computational biology , pharmacogenomics , population , drug , docking (animal) , biology , tirapazamine , drug resistance , homology modeling , gene , genetics , hypoxia (environmental) , mutation , hif1a , bioinformatics , pharmacology , cancer research , chemistry , medicine , biochemistry , nursing , environmental health , organic chemistry , cytotoxicity , oxygen , in vitro , enzyme

Tumor hypoxia, a predominant feature of solid tumor produces drug resistance that significantly impacts a patient's clinical outcomes. Hypoxia-inducible factor 1-alpha (HIF1α) is the major mutation involved in establishing the microenvironment. As a consequence of its involvement in pathways that enable rapid tumor growth, it creates resistance to chemotherapeutic treatments. The propensity of medications to demonstrate drug action often diverges according to the genetic composition. The aim of this study is therefore to examine the effect of population-dependent drug response variations using mutation models.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research